‘Covaxin’s efficacy expected to be more than 90%’: PGI Rohtak’s V-C

‘Covaxin’s efficacy expected to be more than 90%’: PGI Rohtak’s V-C

The third-phase trial of Bharat Biotech's Covid-19 vaccine candidate, Covaxin will begin from November 20.

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, hopes to get 1,000 healthy volunteers for the third-phase, informed Vice-Chancellor OP Kalra.

"We are hoping to get 1,000 healthy volunteers by Thursday.

Of them, 200 volunteers will be administered the Covaxin initially so that we get to know about their antibody response.

There are three centers in the country where antibody response is studied.

If the response is good in 600 volunteers, then ICMR will take permission for market authentication so that mass production can be done," Kalra said.

He further said, "Two doses will be injected to each volunteer.

The second dose will be administered after 28 days of giving the first dose.” Watch the full video for more.